1. Does indomethacin for closure of patent ductus arteriosus affect cerebral function?
- Author
-
Flisberg A, Kjellmer I, Löfhede J, Löfgren N, Rosa-Zurera M, Lindecrantz K, and Thordstein M
- Subjects
- Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Brain physiopathology, Ductus Arteriosus, Patent diagnostic imaging, Ductus Arteriosus, Patent physiopathology, Humans, Indomethacin administration & dosage, Infant, Newborn, Infant, Premature, Infusions, Intravenous, Ultrasonography, Doppler, Vasoconstriction drug effects, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Brain drug effects, Ductus Arteriosus, Patent therapy, Electroencephalography drug effects, Indomethacin pharmacology
- Abstract
Objective: To study whether indomethacin used in conventional dose for closure of patent ductus arteriosus affects cerebral function measured by electroencephalograms (EEG) evaluated by quantitative measures., Study Design: Seven premature neonates with haemodynamically significant persistent ductus arteriosus were recruited. EEG were recorded before, during and after an intravenous infusion of 0.2 mg/kg indomethacin over 10 min. The EEG was analysed by two methods with different degrees of complexity for the amount of low-activity periods (LAP, "suppressions") as an indicator of affection of cerebral function., Results: Neither of the two methods identified any change in the amount of LAPs in the EEG as compared to before the indomethacin infusion., Conclusion: Indomethacin in conventional dose for closure of patent ductus arteriosus does not affect cerebral function as evaluated by quantitative EEG., (© 2010 The Author(s)/Journal Compilation © 2010 Foundation Acta Paediatrica.)
- Published
- 2010
- Full Text
- View/download PDF